Teva-trained nurses provide your patients with services to help them stay on track, including
Teva’s Shared Solutions® gives personal attention to COPAXONE® patients — patients receive ongoing contact from the team at Shared Solutions® via email, mail, and phone, so you can be confident that they have support every step of the way.
Teva understands that some patients may be at a higher risk of discontinuing therapy. That's why Teva’s Shared Solutions® PLUS provides extra high-touch support so that you can be reassured that these patients are feeling cared for.
Who can benefit most from Teva’s Shared Solutions® PLUS?
Characteristics that may present barriers to compliance/adherence include
Teva’s Shared Solutions® presents the COPAXONE iTracker® — an app that lets patients manage their injection routines using their Apple or Android mobile devices.
With a customizable, user-friendly interface, the COPAXONE iTracker® allows patients to
Teva’s Shared Solutions® cares about helping your patients stay on track with COPAXONE® — that's why patients are offered innovative, interactive injection tracking tools to help them manage their injections and stay compliant.
Not actual size.
The autoject®2 for glass syringe is available through Teva’s Shared Solutions® for free with a physician's prescription.
Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.
COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of
The website you are about to visit does not belong to Teva Neuroscience, Inc. or follow the same terms of service. Some of these websites may also require a third-party account, subscription, or payment to view.
While we carefully choose which websites we link to, we cannot control any changes or actions made by them. As a result, Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of the following site, nor any liability on their behalf.